Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 5.2% – What’s Next?

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) were down 5.2% on Wednesday . The company traded as low as $13.21 and last traded at $12.99. Approximately 306,551 shares changed hands during trading, a decline of 77% from the average daily volume of 1,325,683 shares. The stock had previously closed at $13.70.

Analyst Ratings Changes

A number of research analysts have recently commented on CAPR shares. Cantor Fitzgerald raised their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

The stock has a 50-day moving average of $14.40 and a two-hundred day moving average of $13.93. The company has a market cap of $560.19 million, a P/E ratio of -11.65 and a beta of 4.08.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds have recently bought and sold shares of the company. Farallon Capital Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth about $31,056,000. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after acquiring an additional 700,243 shares during the last quarter. Woodline Partners LP bought a new position in Capricor Therapeutics in the 4th quarter valued at approximately $8,693,000. Altium Capital Management LLC boosted its stake in Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after purchasing an additional 429,000 shares during the last quarter. Finally, Black Diamond Financial LLC purchased a new stake in Capricor Therapeutics during the 4th quarter valued at $3,833,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.